恆瑞醫藥(600276.SH):悉數行使超額配售權、穩定價格行動及穩定價格期結束
格隆匯6月19日丨恆瑞醫藥(600276.SH)公佈,根據本次發行方案,公司同意由整體協調人(代表國際承銷商)於2025年6月19日悉數行使超額配售權,按發售價每股H股股份44.05港元發行33,677,800股H股股份。前述超額配售權悉數行使後,本次發行的H股由224,519,800股增加至258,197,600股。香港聯交所已批準上述超額配售股份上市及買賣,預計該等超額配售股份將於2025年6月24日(星期二)上午9時開始在香港聯交所主板上市交易。經扣除承銷費用及傭金以及公司就悉數行使超額配售權而應付的估計開支後,公司將因發行超額配售股份而收取額外募集資金淨額1,471.5百萬港元。公司擬按招股章程「未來計劃及募集資金用途|一節所載的用途按比例使用額外募集資金淨額。
本次發行有關全球發售的穩定價格期已於2025年6月19日(星期四)(即遞交香港公開發售申請截止日期後第30日)結束。穩定價格經辦人摩根士丹利亞洲有限公司或其聯屬人士或任何代其行事的人士於穩定價格期間進行的穩定價格行動如下:1.在國際發售中超額分配合計33,677,800股H股股份,佔全球發售初步可供認購發售股份總數(行使超額配售權之前)的約15%;2.整體協調人(爲其本身及代表國際承銷商)於2025年6月19日(星期四)按每股H股44.05港元(即全球發售項下每股H股股份的發售價,不包括1%經紀傭金、0.0027%香港證券及期貨事務監察委員會交易徵費、0.00565%香港聯交所交易費及0.00015%香港會計及財務彙報局交易徵費)就合計33,677,800股H股股份悉數行使超額配售權,以促成向已同意延遲交付其根據全球發售認購的部分H股的承配人交付相關H股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.